BioTech IP Review

• Patent Number: U.S. Patent No. 9,593,333 B2
• Filing Date: July 8, 2014 (U.S. application)
• Issue Date: March 14, 2017
• Assignee: Ionis Pharmaceuticals, Inc.
• Expiration: Typically patent term extends 20 years from filing (around mid-2030s, subject to patent term adjustments)

---

What the Patent Covers

U.S. Patent No. 9,593,333 claims methods, compounds and compositions for reducing the expression of apolipoprotein C-III (ApoC-III) mRNA and protein using antisense technology. In plain language:

• It protects modified antisense oligonucleotides designed to specifically bind the ApoC-III messenger RNA (mRNA), blocking its production.
• These agents lower ApoC-III levels in the body, which helps reduce plasma triglycerides and improve lipid profiles in disorders where ApoC-III is pathologically elevated.
• The patent’s claims include treatment methods for familial chylomicronemia syndrome (FCS), Fredrickson Type I dyslipidemia, lipoprotein lipase deficiency, and related metabolic conditions, by administering a therapeutically effective amount of an ApoC-III–targeting antisense compound.

These claims are broad enough to cover both the compound compositions themselves and their therapeutic use, giving Ionis strong IP protection for drugs like olezarsen that lower ApoC-III levels.

---

Why It’s Important

• Blockbuster Therapy Protection: This patent is central to protecting Tryngolza (olezarsen), Ionis’s first independently commercialized drug for FCS — a rare genetic disorder with substantial unmet need and significant projected peak sales.
• Market Exclusivity & Litigation: Ionis is actively defending this patent in litigation against competitors (e.g., Arrowhead Pharma) who are seeking to enter the FCS space with rival RNA-targeting medicines — underscoring its commercial value.
• Strategic Leverage: Because the patent covers both the mechanism (ApoC-III reduction) and specific antisense compositions, it helps maintain Ionis’s exclusivity in a high-value therapeutic niche against alternative RNA technologies.

---

Summary

U.S. Patent No. 9,593,333 was among Ionis’s most important patents because it legally protects the core antisense technology behind olezarsen (Tryngolza) — a first-in-class treatment for familial chylomicronemia syndrome by inhibiting ApoC-III. This patent strengthens Ionis’s revenue prospects and serves as a key competitive barrier in the lipid-lowering rare disease market.